Deborah Fenlon

Deborah Fenlon

Auto-generated profile, based on publicly available information

Deborah Fenlon

College of Human and Health Sciences, Swansea University, Swansea, UK

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
SESuzanne A Eccles
Suzanne A Eccles
EAEric Ofori Aboagye
Eric Ofori Aboagye
SASimak Ali
Simak Ali
AAAnnie S Anderson
Annie S Anderson
JAJo Armes
Jo Armes
ATAlastair M Thompson
Alastair M Thompson
Introduction: Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions into practice. Methods: More than 100 internationally recognised specialist breast cancer scientists, clinicians and healthcare professionals collaborated to address nine thematic areas: genetics, epigenetics and epidemiology; molecular pathology and cell biology; hormonal influences and endocrine therapy; imaging, detection and screening; current/novel therapies and biomarkers; drug resistance; metastasis, angiogenesis, circulating tumour cells, cancer ‘stem’ cells; risk and prevention; living with and managing breast cancer and its treatment. The groups developed summary papers through an iterative process which, following further appraisal from experts and patients, were melded into this summary account. Results: The 10 major gaps identified were: (1) understanding the functions and contextual interactions of genetic and epigenetic changes in normal breast development and during malignant transformation; (2) how to implement sustainable lifestyle changes (diet, exercise and weight) and chemopreventive strategies; (3) the need for tailored screening approaches including clinically actionable tests; (4) enhancing knowledge of molecular drivers behind breast cancer subtypes, progression and metastasis; (5) understanding the molecular mechanisms of tumour heterogeneity, dormancy, de novo or acquired resistance and how to target key nodes in these dynamic processes; (6) developing validated markers for chemosensitivity and radiosensitivity; (7) understanding the optimal duration, sequencing and rational combinations of treatment for improved personalised therapy; (8) validating multimodality imaging biomarkers for minimally invasive diagnosis and monitoring of responses in primary and metastatic disease; (9) developing interventions and support to improve the survivorship experience; (10) a continuing need for clinical material for translational research derived from normal breast, blood, primary, relapsed, metastatic and drug-resistant cancers with expert bioinformatics support to maximise its utility. The proposed infrastructural enablers include enhanced resources to support clinically relevant in vitro and in vivo tumour models; improved access to appropriate, fully annotated clinical samples; extended biomarker discovery, validation and standardisation; and facilitated cross-discipline working. Conclusions: With resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.

3 November 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
CFC Foster
C Foster
DFD Fenlon
D Fenlon
Background: Around 2 million people are living with or beyond cancer in the UK. However, experiences and needs following primary treatment are relatively neglected. Following treatment, survivors may feel particularly vulnerable and face threats to their identity. We present a conceptual framework to inform areas of self-management support to facilitate recovery of health and well-being following primary cancer treatment. Methods: To explain the framework, we draw on data from two studies: UK-wide consultation about cancer patients’ research priorities and survivors’ self-management in the year following primary cancer treatment. Results: Self-confidence may be low following treatment. Recovery includes rebuilding lost confidence. Support to manage the impact of cancer on everyday life was a priority. Self-management support included health professionals, peers, employers, family, friends and online resources. However, support was not always available and confidence to access support could be low. Conclusion: Cancer survivors may struggle to self-manage following primary treatment where confidence is low or support is lacking. Low confidence may be a significant barrier to accessing support. Supporting recovery of self-confidence is an important aspect of recovery alongside physical and psychosocial problems in the context of changing health care and cancer follow-up.

24 June 2011 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
CSChristina Shennan
Christina Shennan
SPSheila Alison Payne
Sheila Alison Payne
DFDeborah Fenlon
Deborah Fenlon

16 July 2014 in Journal of Cancer Survivorship
Verified
Journal Article
Open access
PDF file
CFC. Foster
C. Foster
MBM. Breckons
M. Breckons
PCP. Cotterell
P. Cotterell
DBD. Barbosa
D. Barbosa
LCL. Calman
L. Calman
PSP. W. Smith
P. W. Smith
Purpose Cancer survivors are increasingly expected to manage the consequences of cancer and its treatment for themselves. There is evidence that self-efficacy is important for successful self-management and that this can be enhanced with support. The purpose of this study was to assess self-efficacy to manage problems in the year following primary treatment. Methods This cross-sectional online survey included cancer survivors who had completed their treatment within the past 12 months. Self-efficacy was assessed and variables expected to be associated with self-efficacy were measured using validated scales including quality of life, well-being, illness perceptions, depression and social support. Results One hundred eighty-two respondents (mean age 50; 81 % female) completed the survey. They had been treated for a range of cancers; most commonly breast (45 %). Self-efficacy scores varied between individuals and according to the illness-related task to be managed. Respondents were least confident in managing fatigue and most confident in accessing information about their cancer. Individuals most likely to report low self-efficacy were women, those experiencing higher levels of pain and/or depression, lower well-being scores, lower socio-economic status, low levels of social support, or a more negative perception of cancer. Conclusions Self-efficacy to self-manage problems faced as a consequence of cancer and its treatment can vary widely in the year following treatment. Fatigue may be particularly difficult to manage. Implications for Cancer Survivors Variations in self-efficacy highlight the importance of assessing specific problems faced and people’s confidence to manage them in order to tailor appropriate self-management support.

1 April 2016 in The Breast
Verified
Journal Article
Closed access
SPShani Paluch-Shimon
Shani Paluch-Shimon
OPOlivia Pagani
Olivia Pagani
APAnn H. Partridge
Ann H. Partridge
EBEran Bar-Meir
Eran Bar-Meir
LFLesley Fallowfield
Lesley Fallowfield
FCFatima Cardoso
Fatima Cardoso

12 May 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CFClaire Foster
Claire Foster
JHJoanne Haviland
Joanne Haviland
JWJane Winter
Jane Winter
CGChloe Grimmett
Chloe Grimmett
KSKim Chivers Seymour
Kim Chivers Seymour
MCMembers of the Study Advisory Committee
Members of the Study Advisory Committee
This paper identifies predictors of recovery trajectories of quality of life (QoL), health status and personal wellbeing in the two years following colorectal cancer surgery. 872 adults receiving curative intent surgery during November 2010 to March 2012. Questionnaires at baseline, 3, 9, 15, 24 months post-surgery assessed QoL, health status, wellbeing, confidence to manage illness-related problems (self-efficacy), social support, co-morbidities, socio-demographic, clinical and treatment characteristics. Group-based trajectory analyses identified distinct trajectories and predictors for QoL, health status and wellbeing. Four recovery trajectories were identified for each outcome. Groups 1 and 2 fared consistently well (scores above/within normal range); 70.5% of participants for QoL, 33.3% health status, 77.6% wellbeing. Group 3 had some problems (24.2% QoL, 59.3% health, 18.2% wellbeing); Group 4 fared consistently poorly (5.3% QoL, 7.4% health, 4.2% wellbeing). Higher pre-surgery depression and lower self-efficacy were significantly associated with poorer trajectories for all three outcomes after adjusting for other important predictors including disease characteristics, stoma, anxiety and social support. Psychosocial factors including self-efficacy and depression before surgery predict recovery trajectories in QoL, health status and wellbeing following colorectal cancer treatment independent of treatment or disease characteristics. This has significant implications for colorectal cancer management as appropriate support may be improved by early intervention resulting in more positive recovery experiences.